GLP Research Peptides Wholesale

What this class covers, and the codes we retired

GLP research is the class for the incretin-analogue research peptides and the amylin analogue that is ordered alongside them. As materials they are the most alike of anything in the catalog: long synthetic peptides, each supplied as lyophilized powder in a sealed vial and listed in milligrams of solid per vial.

What distinguishes them is the receptor family each molecule was designed against, which is how the identity data on each product page describes them. Semaglutide is described as a GLP-1 receptor agonist peptide. Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide. Retatrutide is a GIP, GLP-1 and glucagon receptor triple agonist peptide. Cagrilintide is not an incretin analogue at all but an acylated, lipidated amylin analogue at 4409 g/mol, CAS 1415456-99-3.

Those are structural descriptions of what the molecule is, not statements about what the material does in any system. These compounds are supplied for laboratory research use only, and nothing on this site describes use, preparation or outcome for any of them.

Until 1 November 2026 the three incretin analogues in this class were listed under internal codes rather than compound names: VLP-1 (SM) for Semaglutide, VLP-2 (TR) for Tirzepatide and VLP-3 (RT) for Retatrutide. The codes are retired, and the catalog now lists all three under their compound names.

The codes do still appear on each product page as synonyms, for one reason: the published laboratory reports were issued under them. Keeping the old name visible means the paper trail stays legible instead of being tidied away. If you hold an older quote or a report that names VLP-1, VLP-2 or VLP-3, it maps to Semaglutide, Tirzepatide and Retatrutide in that order, and the current product page for each lists the same reports.

We list compounds by compound name only. No pharmaceutical brand name belongs on a research-supply listing, and you will not find one here or on a quote.

What we list, by name and size

That is thirteen published reports across four products, every one of them matched to a size we actually list. This class is the most thoroughly documented in the catalog on a per-size basis, which is the point of listing the sizes and the reports in the same table.

The 5 mg to 30 mg ladder exists so a buyer can take the same compound at the vial size their work is set up around. If you need a size that is not on the ladder, ask in the inquiry rather than assuming: the quote will tell you what the factory can supply.

• Semaglutide - 5 mg, 10 mg, 20 mg and 30 mg. A published report for each of the four sizes.
• Tirzepatide - 5 mg, 10 mg, 20 mg and 30 mg. A published report for each of the four sizes.
• Retatrutide - 5 mg, 10 mg, 20 mg and 30 mg. A published report for each of the four sizes.
• Cagrilintide - 10 mg. One published report, at 10 mg.

What the published reports cover

Every report in this class comes from Kovera Labs. Each prints purity by RP-HPLC at 214 nm, identity by LC-MS and a net content figure in milligrams against the labelled size, and each is published in full and linked from the Report column above.

Because each size is documented separately, a report on a 30 mg vial is not evidence about a 5 mg vial, and the catalog never treats it as one. The table pairs each product with the report for the size it covers, and the Published purity column quotes the figure exactly as printed. The Cagrilintide report, for instance, prints 99.718%. We would rather you open the document than take a class-wide average from us, because there is no such average and we do not publish one.

What a report does not do is prove that its printed batch is the batch in current wholesale inventory. That has not been established for any lot, which is why a quote names the lot you would receive and that lot's report, and why every wholesale lot ships with its certificate of analysis. Of the four compounds, Cagrilintide has a publication statistics page under its product page; the hub for all our literature pages is /research.

How to order from this class

Sizes are the amount in one vial and quantity is the number of vials. Nothing in the catalog is priced and no minimum is published: build the list you want and we quote it as it stands.

Mixing sizes in one inquiry is the normal case here, not an exception. A list might hold Semaglutide at 5 mg and at 30 mg, Tirzepatide at 10 mg, Cagrilintide at 10 mg and a couple of items from peptides, all in one message.

The reply names pricing, current availability, the lot you would receive and its report. Wholesale stock, white label and 3PL ship from Tampa Bay, Florida to the United States. A factory-direct order comes from the manufacturer rather than our shelf and can ship internationally, which is the route for volumes above what we hold. How ordering works covers both.

White label and 3PL in this class

This is the class most new research brands ask about first, and it is the one where documentation matters most to their buyers. White label puts your brand on the vial, label and carton from these lots. 3PL fulfillment stores your finished stock in Tampa Bay and ships it out as your brand, so your customer never sees ours.

Decide two things before you ask: which points on the 5 mg to 30 mg ladder you want to carry, since each is a separate SKU with its own report, and whether your store needs to publish the reports for the lots you hold. If the brand also needs the store and a way to take cards, websites and payment processing come from the same team, and we build for research-supply brands only.

What we source in this class beyond the four

The four listed products are what we hold in this class. Several further incretin analogues are sourced to order rather than stocked: Liraglutide, Dulaglutide, Survodutide and Mazdutide.

A sourced compound is not in stock, and its page says so plainly: what the material is, that we get it to order, and that availability, sizes and pricing come back on the quote. Put sourced and stocked items on the same list and you get one quote covering both. See everything we source.